Schizophrenia Research
Volume 77, Issue 2 , Pages 129-139 , 15 September 2005

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

Received 18 November 2004 ,Revised 15 March 2005 ,Accepted 17 March 2005.

References 

  1. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry. 2001;179:290–299
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth ed.. Washington, DC: American Psychiatric Association; 2000;
  3. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry. 2003;64:1342–1348
  4. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry. 1999;174:23–30
  5. Chen JY, Bai YM, Pyng LY, Lin CC. Risperidone for tardive dyskinesia. Am. J. Psychiatry. 2001;158:1931–1932
  6. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J. Clin. Psychopharmacol. 1995;15(1 Suppl 1):36S–44S
  7. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am. J. Psychiatry. 1979;136:79–82
  8. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can. J. Neurol. Sci. 1980;7:233
  9. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 1988;8(4 Suppl):21S–26S
  10. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004;161:414–425
  11. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int. J. Geriatr. Psychiatry. 2000;15:506–514
  12. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry. 2003;64:1250–1257
  13. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr. Res. 2005;77:119–128
  14. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry. 2000;61(Suppl 3):16–21
  15. Jeste DV, Glazer WM, Morgenstern H, Pultz JA, Yeung PP. Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. In: Poster presented at: The 38th Annual Meeting of the American College of Neuropsychopharmacology. Acapulco, Mexico, December 12–16. 1999;
  16. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 1999;47:716–719
  17. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am. J. Geriatr. Psychiatry. 1999;7:70–76
  18. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry. 2000;157:1150–1155
  19. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J. Affect. Disord. 2004;83:263–275
  20. Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int. J. Geriatr. Psychiatry. 2004;19:898–905
  21. Marder SR. Depot neuroleptics: side effects and safety. J. Clin. Psychopharmacol. 1986;6(1 Suppl):24S–29S
  22. Rodnitzky RL. Drug-induced movement disorders. Clin. Neuropharmacol. 2002;25:142–152
  23. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 1982;39:486–487
  24. Sethi KD. Movement disorders induced by dopamine blocking agents. Semin. Neurol. 2001;21:59–68
  25. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J. Clin. Psychopharmacol. 1997;17:194–201
  26. Soares, K., Rathbone, J., Deeks, J., 2004. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. CD000203.
  27. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry. 1997;154:1248–1254

PII: S0920-9964(05)00125-8

doi: 10.1016/j.schres.2005.03.015

Schizophrenia Research
Volume 77, Issue 2 , Pages 129-139 , 15 September 2005

Article Tools

* Image Usage & Resolution